Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.

Prentice, RE; Tjandra, D; Garg, M; Lubel, JS; Fourlanos, S; Johnson, D; Al-Ani, A; Christensen, B

Citations

Altmetric

Author

Prentice, RE; Tjandra, D; Garg, M; Lubel, JS; Fourlanos, S; Johnson, D; Al-Ani, A; Christensen, B

Date

2020-10

Source Title

Alimentary Pharmacology and Therapeutics

University of Melbourne Author/s

Fourlanos, Spiros; Johnson, Douglas; Garg, Mayur

Affiliation

Medical Education
Medicine (RMH)

Metadata

Show full item record

Document Type

Journal Article

Citations

Prentice, R. E., Tjandra, D., Garg, M., Lubel, J. S., Fourlanos, S., Johnson, D., Al-Ani, A. & Christensen, B. (2020). Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.. Aliment Pharmacol Ther, 52 (8), pp.1422-1423. https://doi.org/10.1111/apt.16063.

Access Status

Access this item via the Open Access location